President Trump’s executive order to reduce the cost of prescription drugs in the United States has sparked speculation and uncertainty among pharmaceutical executives and industry experts. The plan, which aims to implement a “most favored nation” model tying drug prices in the U.S. to those of comparably wealthy nations, lacks crucial details needed for its successful implementation.
The key premise of the most favored nation model is to select the lowest price among economically similar nations with at least 60% of the U.S. gross domestic product per capita. However, the lack of specific price targets, accounting for purchasing power disparities, and incorporating utilization and formulation differences between countries raise significant challenges.
Furthermore, the complexity deepens for pharmaceutical companies with the absence of generic or biosimilar competition for certain drugs in the U.S. compared to other nations. The timing of drug approvals and launches across countries also presents obstacles in creating an international price index for prescription medications.
The executive order proposed the establishment of a direct-to-consumer platform for Americans to purchase drugs at the most favored nation price directly from manufacturers. However, the logistics of building such a platform and the unfamiliarity of drug companies with direct sales to patients pose additional hurdles.
The administration’s plan to impose most-favored-nation pricing through a rulemaking plan remains vague, with potential utilization of a demonstration project in the Medicare program. Yet, the historical limitations of Center for Medicare and Medicaid Innovation (CMMI) projects and the uncertainty surrounding the voluntary or mandatory nature of the most favored nation model raise concerns among healthcare providers and industry stakeholders.
With President Trump’s promise of immediate reductions in drug prices upon the implementation of the most favored nation plan, the lack of clarity and potential legal challenges pose significant obstacles to achieving the projected cost savings. As the pharmaceutical industry awaits further details and guidance, the path to lower prescription drug prices in the U.S. remains uncertain and fraught with challenges.
